Showing results (171-180 of 299) with videos related to
Sort By:
Pageof 30
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590Heather A Wakelee, Patricia Stephenson, Steven M Keller, et al.Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2011
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapyVicki Leigh Keedy, Sarah Temin, Mark R Somerfield, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 18, 2011
Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smokedScarlett L Gomez, Ellen T Chang, Sarah J Shema, et al.Cancer Investigation|February 25, 2012
Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancerJonathan W Riess, Aaron C Logan, Yelena Krupitskaya, et al.NPJ Digital Medicine|November 29, 2025
Leveraging large language models to extract smoking history from clinical notes for lung cancer surveillanceIngrid Luo, Anna Graber-Naidich, Mengrui Zhang, et al.Journal of Thoracic Disease|March 31, 2018
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapyMatthew A Gubens, Jody C Chuang, Wallace Akerley, et al.Lung Cancer (Amsterdam, Netherlands)|July 20, 2012
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.Clinical Lung Cancer|June 26, 2022
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based RegimensSarah Waliany, Heather Wakelee, Kavitha Ramchandran, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2010
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancerChristelle Clément-Duchêne, Yelena Krupitskaya, Kristen Ganjoo, et al.Pageof 30